Matthew Powell, MD

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Matthew Powell, MD, presents findings from a second interim analysis of part 1 from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial investigating the combination of dostarlimab-gxly plus carboplatin/paclitaxel compared with placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer.

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

An overview of ongoing research in the endometrial cancer treatment space.

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

Matthew Powell, MD, presents data from the blinded independent central review of the RUBY trial, which studied dostarlimab in patients with primary advanced or recurrent endometrial cancer.

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses tumor mutational burden (TMB) in ovarian cancer.

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses the future of immunotherapy in ovarian cancer.

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses data with immunotherapy in ovarian cancer.

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses microsatellite instability and mismatch repair deficiency as potential biomarkers in endometrial cancer.

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses immunotherapy in ovarian cancer.